ACB $5.050 (-2.88%)

ACNNF $0.101 (0.5%)

AERO $2.970 (-0.34%)

AGEEF $0.050 (0.3%)

ALEAF $0.358 (2.9%)

AMMJ $0.063 (-2.93%)

APHA $4.230 (0.24%)

ARNA $73.690 (0.89%)

ATT:CNX $0.080 (0%)

ATTBF $0.006 (-5.88%)

AUSA:CNX $0.135 (0%)

AUSAF $0.100 (-4.54%)

AVXL $3.870 (0%)

BAMM:CNX $0.350 (-5.41%)

BBM:CNX $0.050 (11.11%)

BBRRF $0.040 (4.16%)

BE:CNX $0.005 (0%)

BIO:CNX $0.065 (0%)

BLEVF $0.003 (-3.13%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.420 (0%)

BLOZF $0.315 (-1.44%)

BUDZ $0.199 (-0.35%)

BXNG $0.510 (8.49%)

CADMF $0.562 (1.32%)

CALI:CNX $0.075 (0%)

CANN $0.300 (1.01%)

CARA $12.940 (-3%)

CBII:CNX $0.195 (11.43%)

CBIIF $0.150 (12.71%)

CBWTF $0.097 (-3%)

CGC $14.170 (-0.7%)

CGRW $0.070 (-4.11%)

CHOO:CNX $0.075 (7.14%)

CHOOF $0.060 (2.21%)

CNBX $0.157 (-4.85%)

CNGGF $0.290 (7.41%)

CODI $17.690 (2.37%)

CPMD $0.630 (14.55%)

CRBP $1.565 (1.62%)

CRON $5.080 (-0.97%)

CROP:CNX $0.015 (0%)

CRTPF $2.230 (19.86%)

CRXPF $0.056 (50.5%)

CSI:CNX $0.920 (0%)

CURR $1.300 (0.78%)

CVSI $0.500 (-3.85%)

DIGP $0.023 (-8.06%)

DXBRF $0.140 (0%)

EAPH $0.001 (0%)

EAT:CNX $0.013 (-16.67%)

EEVVF $0.051 (-4.85%)

EMHTF $0.145 (0.28%)

EPWCF $0.024 (0%)

EVIO $0.011 (0.92%)

FFRMF $0.019 (-21.81%)

FFT:CNX $0.040 (0%)

FNNZF $0.053 (2.3%)

GGTTF $0.072 (9.31%)

GLDFF $0.017 (7.1%)

GLH:CNX $0.020 (-20%)

GNBT $0.240 (34.83%)

GRIN:CNX $0.105 (0%)

GRWG $15.060 (1.83%)

GSTR:CNX $0.070 (7.69%)

GTBIF $12.360 (0.26%)

GTII:CNX $16.550 (0.61%)

GWPH $100.440 (1.97%)

HEXO $0.658 (2.11%)

HLSPY $0.405 (0%)

HMLSF $4.374 (1.48%)

HMPPF $0.498 (0%)

HRVOF $0.047 (-16.22%)

HSTRF $0.078 (-1.4%)

HUGE:CNX $3.560 (0%)

IAN:CNX $0.090 (20%)

IGC $1.030 (-1.9%)

IGXT $0.149 (0%)

IIPR $123.360 (3.39%)

IMLFF $3.570 (0.28%)

INQD $0.002 (-13.04%)

IONC:CNX $0.015 (0%)

IONKF $0.010 (-36.71%)

ISOL:CNX $0.035 (0%)

ISOLF $0.025 (0%)

ITHUF $0.068 (6.54%)

IVITF $0.009 (0.56%)

JWCAF $0.002 (48.15%)

KBEV:CNX $0.050 (0%)

KBEVF $0.038 (0.79%)

KHRNF $0.350 (3.28%)

KSHB $0.523 (-5.82%)

LHS:CNX $0.510 (0%)

LHSIF $0.388 (4.16%)

LOVE:CNX $0.095 (0%)

LXRP $0.260 (-7.14%)

LXX:CNX $0.360 (-4%)

MCIG $0.028 (0%)

MEDIF $0.640 (6.46%)

MGWFF $0.048 (-12.55%)

MICWF $0.078 (0%)

MJ:CNX $0.035 (0%)

MJNA $0.014 (-0.37%)

MNTR $0.076 (-4.27%)

MRRCF $0.004 (10%)

MWM:CNX $0.140 (40%)

MYM:CNX $0.050 (-9.09%)

MYMMF $0.040 (-4.76%)

NCNNF $0.150 (10.29%)

NDVAF $0.182 (-4.21%)

NGW:CNX $0.205 (5.13%)

NRXCF $0.100 (0%)

NSPDF $0.048 (15.14%)

NTEC $0.248 (2.18%)

NVTQF $0.451 (0%)

NWKRF $0.424 (0%)

NXGWF $0.154 (0.77%)

NXTTF $0.191 (-2.61%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

OWCP $0.008 (-1.25%)

PHCG $0.350 (6.06%)

PHVAF $0.038 (0%)

PILL:CNX $0.720 (2.86%)

PKG:CNX $0.075 (-6.25%)

PLPRF $0.428 (-3.61%)

PLUS:CNX $0.570 (-3.39%)

PMCB $0.015 (11.19%)

PNPL $0.200 (0%)

POTN $0.013 (-0.76%)

PRCNF $0.012 (20.6%)

PTNYF $0.061 (1.67%)

QCA:CNX $0.120 (4.35%)

RDDTF $0.080 (-5%)

RLLVF $0.034 (9.45%)

RMHB $0.051 (-0.98%)

RQB:CNX $0.005 (0%)

RQHTF $0.169 (-2.03%)

RVVQF $0.008 (1.27%)

SLNG:CNX $0.125 (4.17%)

SMG $149.150 (1.47%)

SNN:CNX $0.155 (0%)

SNNVF $0.111 (21.98%)

SOL:CNX $1.170 (30%)

SOLCF $0.870 (29.06%)

SPLIF $0.008 (-24.56%)

SPRWF $0.114 (4.6%)

SRNA $0.021 (-2.73%)

STEM:CNX $0.370 (0%)

STMH $0.310 (8.76%)

SUN:CNX $0.170 (6.25%)

TBPMF $0.105 (-2.79%)

TCAN:CNX $0.880 (-3.3%)

TCNAF $0.662 (-6.45%)

TER:CNX $5.700 (5.56%)

TGEN $0.830 (10.68%)

TGIF:CNX $0.055 (-8.33%)

TGIFF $0.046 (0.88%)

THC:CNX $0.115 (-4.17%)

THCBF $0.090 (-6.62%)

TLRY $4.790 (0.84%)

TOKI:CNX $0.030 (0%)

TRLFF $0.025 (0.4%)

TRSSF $4.300 (6.17%)

TRTC $0.075 (2.6%)

TURV $0.085 (-5.61%)

VBIO $0.170 (0.35%)

VIDA:CNX $0.055 (0%)

VIN:CNX $0.015 (0%)

VPRB $0.022 (3.61%)

VRNDF $0.422 (-0.48%)

VRT:CNX $0.150 (0%)

VRTHF $0.115 (0%)

VVCIF $0.140 (9.41%)

WAYL:CNX $0.740 (0%)

WDDMF $0.217 (-3.26%)

WLDFF $0.125 (0.08%)

XXII $0.628 (11.11%)

ZDPY $0.320 (10.34%)

ZYNE $3.280 (1.55%)

Technical420 Site Search

Returned 424 result(s).

Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application to commence a Phase II/III,…

Here Is What To Expect From Aurora Cannabis Upcoming Year End Earnings Release and Conference Call

Later this month, Aurora Cannabis Inc. (ACB.TO) (ACB) will host its first quarterly investor conference under new CEO Miguel Martin and this is an event that we will be tuning into. 2020 has been a roller-coaster for the Canadian cannabis producer and we expect the fourth quarter financial results to…

Will Canopy Growth Be Able To Compete In A Highly Saturated CBD Market?

Canopy Growth Corporation (WEED.TO) (CGC) is a leading global cannabis company that has been executing on a series of growth initiatives that are focused around enhancing brand awareness. One of the ways the Canadian cannabis producer has been able to accomplish this is through strategic partnerships with celebrities like Snoop…

Hemptown Announces LOI for Proposed Qualifying Transaction with Spectre Capital Corp.

Hemptown Organics Corp., a privately held British Columbia company, is pleased to announce it has entered into a letter of intent (the "LOI") with Spectre Capital Corp. (TSXV: SOO.P), a capital pool company listed on the TSX Venture Exchange (the "Exchange"), in relation to the acquisition (the “Transaction”) of all the…

Will Aurora Cannabis Inc’s New CEO Be Able To Restore Investor Confidence?

Earlier this week, Aurora Cannabis Inc. (ACB.TO) (ACB) provided an update on its business operations along with certain unaudited preliminary fourth quarter financial results. In the update, the company announced the appointment of Miguel Martin as its new CEO and we will monitor how he is able to drive the…

World High Life Investment Strategy Update

World High Life Plc (AQSE:LIFE)(OTCQB:WRHLF) is pleased to announce that, in accordance with the Company's investment strategy, and building upon momentum from its wholly owned subsidiary, London based Love Hemp Limited ("Love Hemp"), the Company is now actively considering investment targets in the medicinal cannabis space, including new technologies and…

Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx(TM)

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, is pleased to announce the initiation of its Health Canada approved Phase 1 clinical study of CardiolRx™. CardiolRx…

CEO Spotlight: Christian Schenk of Driven Deliveries

Welcome to Technical420! Today, we are fortunate to have Christian Schenk, CEO of Driven Deliveries (DRVD), join us to discuss the Driven platform and how they are capitalizing on current cannabis sector trends. Driven is the first licensed & vertically integrated, publicly traded, online cannabis retailer servicing 92% of California…

Cardiol Therapeutics Could Be Sitting On A Breakthrough Therapy To Treat A Major Covid-19 Related Condition

Following the COVID pandemic, the level of safety in college sports has come under heavy scrutiny and has become one of the most highly talked about subjects. One of the most significant health concerns that is associated with college athletes in the COVID era is Myocarditis, which is the inflammation…

GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress

GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the second quarter ended June 30, 2020. “We were pleased with the strength of U.S. Epidiolex sales in the second quarter in spite of…

Older Posts »

Search Again